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A B S T R A C T
Four binuclear phosphanesilver(I) dithiocarbamates, {cyclohexyl3PAg(S2CNRR′)}2 for R=R′= Et (1), CH2CH2
(2), CH2CH2OH (3) and R=Me, R′= CH2CH2OH (4) have been synthesised and characterised by spectroscopy
and crystallography, and feature tri-connective, μ2-bridging dithiocarbamate ligands and distorted tetrahedral
geometries based on PS3 donor sets. The compounds were evaluated for anti-bacterial activity against a total of
12 clinically important pathogens. Based on minimum inhibitory concentration (MIC) and cell viability tests
(human embryonic kidney cells, HEK 293), 1–4 are specifically active against Gram-positive bacteria while
demonstrating low toxicity; 3 and 4 are active against methicillin resistant S. aureus (MRSA). Across the series, 4
was most effective and was more active than the standard anti-biotic chloramphenicol. Time kill assays reveal
1–4 to exhibit both time- and concentration-dependent pharmacokinetics against susceptible bacteria.
Compound 4 demonstrates rapid (within 2 h) bactericidal activity at 1 and 2×MIC to reach a maximum de-
crease of 5.2 log10 CFU/mL against S. aureus (MRSA).
1. Introduction
The inexorable emergence of anti-biotic resistant bacteria to mul-
tiple anti-bacterial agents is now recognised as a significant global
health threat worldwide as there are fewer or even no effective anti-
biotic treatments available for these infectious pathogens [1]. The
problem arises in part due to selective stress exerted on bacteria that is
driven by the use and misuse of anti-bacterial agents in food producing
animals and patients. This pressure has forced the quickly replicating
bacteria to develop resistance mechanisms [2,3]. This worrying situa-
tion highlights the urgent need to develop novel and selective anti-
bacterial drugs. The real challenge remains to develop new anti-bac-
terial agents with new mechanisms of action that can overcome ac-
quired resistance without contributing to resistance development [4].
Historically, metal-based drugs have been used as drugs to treat a
variety of diseases, i.e. platinum compounds, e.g. cisplatin, carboplatin
and oxaliplatin, are the most widely used cancer therapeutic agents,
and gold compounds, e.g. myocrisin and auranofin, are used for the
treatment of rheumatoid arthritis [5]. Notably, silver and its com-
pounds [6,7] and silver-based nanoparticles [8] have long been known
to possess strong inhibitory and bactericidal effects as well as a broad
spectrum of anti-microbial activities for bacteria, fungi and viruses, and
continue to attract significant attention [9–12]. Silver generally ex-
hibits higher toxicity to microorganisms with lower toxicity to mam-
malian cells compared with other metals [13].
Recent studies have highlighted metal dithiocarbamate derivatives,
My(S2CNRR′)y, as potential metal-based drugs to combat bacterial in-
fection [14]. Thus, over the years, various transition metal complexes
[15–17] and main group element dithiocarbamate compounds [18–21]
have been investigated in this context and interest continues with a
focus of recent research being upon coinage metal dithiocarbamates,
i.e. of copper(I) and silver(I) [22] and of gold(I) [23,24]. In the latter
studies, emphasis has moved away from R, R′= alkyl compounds to
include hydroxyethyl substituents owing to the possibility of enhanced
hydrophilicity of the resultant compounds. Noteworthy results from
these previous biological assays include the observation that the anti-
bacterial activity of a series phosphanegold(I) dithiocarbamates, R3PAu
[S2CN(iPr)CH2CH2OH] for R=Et, cyclohexyl (Cy) and Ph, were found
to be dependent on the nature of the phosphane-bound substituent.
While the R=Cy and Ph derivatives exhibited specific activity against
Gram-positive bacteria, the R=Et compound showed broad range ac-
tivity against both Gram-positive and Gram-negative bacteria [23].
Also, based on time kill studies the R=Cy and Ph compounds were
bactericidal whereas the R=Et compound was bactericidal and
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bacteriostatic depending on the specific bacterial strain investigated
[23]. In a latter study, a series of bis(triphenylphosphane)-copper (I)
and -silver(I) dithiocarbamates were investigated as new anti-bacterial
agents and revealed activities dependent upon both phosphane- and
dithiocarbamate-bound substituents [22].
Reflecting the interesting results obtained for the ternary phos-
phane-copper (I) and silver(I) dithiocarbamate compounds in tackling
pathogens and in recognition of the potential of silver dithiocarbamates
as effective anti-bacterial agents, the preceding studies were extended
to the four compounds shown in Fig. 1, i.e. containing tricyclohex-
ylphosphane co-ligands. Herein, a study was conducted to determine
the efficacy of 1–4 as potential anti-bacterial agents against a range of
Gram-positive and Gram-negative bacteria using disc diffusion, MIC
and MBC assays. To further determine the preliminary pharmacoki-
netics of these complexes, time kill assays were employed to assess
whether the treated bacteria were bactericidal or bacteriostatic. The
cytotoxicity effects of 1–4 were evaluated through a MTT (3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay on normal
cells, i.e. HEK 293 human embryonic kidney epithelial cells.
2. Experimental
2.1. Materials
All chemicals and solvents were used as received. Reactions were
carried out under ambient conditions. The sodium diethyldithiocarba-
mate trihydrate (BDH Chemicals) and ammonium pyrrolidinedithio-
carbamate (Sigma-Aldrich), tricyclohexylphosphane (Cy3P; Sigma-
Aldrich) and AgNO3 (Systerm) were obtained from commercial sources.
The hydroxyethyl dithiocarbamate ligands, −S2CN(R)CH2CH2OH for
R=CH2CH2OH and Me, as K+ or NH4+ salts, were prepared as per an
earlier study [25].
2.2. Instrumentation
Melting points were determined on an Automatic Melting Apparatus
MP450 (Biobase, China). Elemental analyses were performed on a Leco
TruSpec Micro CHN Elemental Analyser. IR spectra were obtained on a
Vertex 70v FTIR Spectrometer (Bruker, Germany); abbreviations:
s= strong; m=medium. 1H, 13C{1H} and 31P{1H} NMR spectra were
recorded in CDCl3 solution at 25 °C on a Bruker Ascend 400MHz NMR
spectrometer with chemical shifts relative to tetramethylsilane (in-
ternal; 1H and 13C{1H}) and triphenylphosphate (external; 31P{1H})
reference; abbreviations for NMR assignments: s= singlet; d= doublet;
t= triplet; q= quartet; sept= septet; m=multiplet; br= broad.
2.3. Synthesis and characterisation
2.3.1. Bis{tricyclohexylphosphanesilver(I) N,N-diethyldithiocarbamate}
(1)
Cy3P (1mmol; 0.280 g) dissolved in acetonitrile (10mL) was added
to an acetonitrile solution (10mL) of AgNO3 (1mmol; 0.170 g) at room
temperature. Then, Na[S2CNEt2]·3H2O (1mmol; 0.225 g) dissolved in
ethanol (10mL) was added followed by stirring for 4 h. The resulting
mixture was filtered and evaporated to yield a yellow solid. The solid
was recrystallized from a dichloromethane and methanol solution
(4mL; 1/1 v/v) via slow evaporation, yielding yellow crystals. Yield:
65%. M.p.: 197.7 °C. Anal. calc. for C23H43AgNPS2: C, 51.48; H, 8.08; N,
2.61. Found: C, 51.55; H, 8.43; N, 2.65. IR (cm−1): 1473 (m) ν(CeN);
1073 (m), 991 (m) ν(CeS). 1H NMR: δ 3.98 (q, 4H, CH2, JH-
H= 6.96 Hz), 1.32 (t, 6H, CH3, JH-H= 7.04 Hz), 1.89–1.20 (m, br, 33H,
Cy3P) ppm. 13C{1H} NMR: δ 209.2 (Cq), 49.2 (CH2), 31.9 (d, α-C6H11,
JC-P= 14.57 Hz), 31.1 (d, β-C6H11, JC-P= 4.54 Hz), 27.3 (d, γ-PC6H11,
JC-P= 11.64 Hz), 26.0 (d, δ-C6H11, JC-P= 0.84 Hz), 12.2 (CH3) ppm.
31P{1H} NMR: δ 40.0 (d, J107Ag-P= 552.15, J109Ag-P= 625.00 Hz) ppm.
2.3.2. Bis{tricyclohexylphosphanesilver(I) N,N-pyrrolidinedithiocarbamate} (2)
Compound 2 was prepared as for 1 but using NH4[S2CN(CH2CH2)2]
(1mmol; 0.164 g) as the dithiocarbamate ligand. Yield: 41%. M.p.:
199.9 °C. Anal. calc. for C23H41AgNPS2: C, 51.68; H, 7.73; N, 2.62.
Found: C, 51.51; H, 7.77; N, 2.67. IR (cm−1): 1423 (s) ν(CeN); 1032
(m), 996 (m) ν(CeS). 1H NMR: δ 3.82 (t, 4H, NCH2, JH-H= 6.44 Hz),
2.00 (t, 4H, CH2, JH-H= 6.54 Hz), 1.92–1.17 (m, br, 33H, Cy3P) ppm.
13C{1H} NMR: δ 205.7 (Cq), 49.2 (NCH2), 31.9 (d, α-C6H11, JC-
P= 14.46 Hz), 31.1 (d, β-PC6H11, JC-P= 4.39 Hz), 27.3 (d, γ-C6H11, JC-
P= 11.31 Hz), 26.6 (CH2), 26.0 (δ-C6H11) ppm. 31P{1H} NMR: δ 40.0
(d, J107Ag-P= 548.75, J109Ag-P= 631.52 Hz) ppm.
2.3.3. Bis{tricyclohexylphosphanesilver(I) N,N-dihydroxyethyldithio
carbamate} (3)
The compound was prepared from the in situ reaction of AgNO3,
Cy3P and K[S2CN(CH2CH2OH)2] in a 1:1:1 ratio. AgNO3 (1mmol;
0.170 g) was stirred with Cy3P (1mmol; 0.280 g) in acetonitrile (10mL)
at room temperature to obtain a suspension. To this K[S2CN
(CH2CH2OH)2] (1mmol; 0.219 g) in water (4mL)/ethanol (6mL)
mixture was added followed by stirring for 2 h. Chloroform (20mL) was
added and stirring was continued for another 2 h, after which the
yellow chloroform solution was separated. The organic solution was
dried over MgSO4, filtered and slowly evaporated to yield a bright-
yellow gel. A minimum volume of hexane (2mL) was added to this gel
while stirring vigorously until precipitation occurred. The yellow pre-
cipitates were isolated through filtration. Recrystallization was per-
formed in methanol via slow evaporation, yielding yellow block crys-
tals. Yield: 60%. M.p.: 180.2 °C. Anal. calc. for C23H43AgNO2PS2: C,
48.59; H, 7.62; N, 2.46. Found: C, 48.71; H, 7.93; N, 2.54. IR (cm−1):
1448 (s) ν(CeN); 1066 (s), 985 (s) ν(CeS). 1H NMR: δ 4.24 (s, br, 4H,
OCH2), 4.09 (s, br, 4H, NCH2), 3.26 (s, br, 2H, OH), 1.89–1.27 (m, br,
33H, Cy3P) ppm. 13C{1H}: δ 213.4 (Cq), 61.2 (OCH2), 59.1 (NCH2),
32.0 (d, α-C6H11, JC-P= 14.09 Hz), 31.1 (d, β-C6H11, JC-P= 4.43 Hz),
27.3 (d, γ-C6H11, JC-P= 11.59 Hz), 26.0 (δ-C6H11) ppm. 31P{1H} NMR:
δ 39.4 (d, br, JAg-P= 590.94 Hz) ppm.
2.3.4. Bis{tricyclohexylphosphanesilver(I) N-hydroxyethyl-N-methyldithio
carbamate} (4)
AgNO3 (1mmol; 0.170 g) was stirred with Cy3P (1mmol; 0.280 g)
in acetonitrile (10mL) at room temperature to yield a suspension. Then,
Fig. 1. Chemical structures of 1–4.
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NH4[S2CN(Me)CH2CH2OH)] (1mmol; 0.168 g) in water (10mL) was
added which was then stirred for 2 h. Chloroform (20mL) was added
and stirring was continued for another 2 h, after which the yellow
chloroform solution was separated. The solution was filtered and eva-
porated to yield a yellow solid. The crystals were obtained from di-
chloromethane by slow evaporation. Yield: 71%. M.p.: 183.3 °C. Anal.
calc. for C22H41AgNOPS2: C, 49.07; H, 7.67; N, 2.60. Found: C, 48.93;
H, 8.13; N, 2.47. IR (cm−1): 1443 (m) ν(CeN); 1043 (m), 993 (m)
ν(CeS). 1H NMR: δ 4.20 (t, 2H, OCH2, JH-H= 5.20 Hz), 4.01 (t, 2H,
NCH2, JH-H= 5.00 Hz), 3.56 (s, 3H, CH3), 2.64 (s, br, 1H, OH),
1.88–1.17 (m, br, 33H, Cy3P) ppm. 13C{1H} NMR: δ 212.1 (Cq), 61.0
(OCH2), 59.1 (NCH2), 44.5 (CH3), 32.0 (d, α-C6H11, JC-P= 14.26 Hz),
31.1 (d, β-PC6H11, JC-P= 4.54 Hz), 27.3 (d, γ-C6H11, JC-P= 11.54 Hz),
26.0 (δ-C6H11) ppm. 31P{1H} NMR: δ 39.7 (d, J107Ag-P= 554.91, J109Ag-
P= 629.68 Hz) ppm.
2.4. Single crystal X-ray structure determinations
Intensity data for 1–4 were measured at 100 K on an Rigaku/Oxford
Diffraction XtaLAB Synergy diffractometer (Dualflex, AtlasS2) using
CuKα radiation (λ= 1.54178 Å). Data reduction and Gaussian ab-
sorption corrections were by standard methods [26]. The structures
were solved by direct methods [27] and refined on F2 with anisotropic
displacement parameters and C-bound H atoms in the riding model
approximation [28]. For 3 and 4, the O-bound H atoms were located
from Fourier difference maps but refined with OeH constrained to
0.84 ± 0.01 Å. A weighting scheme of the form w=1 /
[σ2(Fo2)+ (aP)2+ bP] where P= ((Fo2+ 2Fc2) / 3) was introduced in
each case. In the refinement of 2, a second position was detected for the
Ag1 with the minor component, after unrestrained refinement, having a
site occupancy= 0.280(14); no evidence for other disordered atoms
was found. The maximum and minimum residual electron density peaks
of 1.15 and 0.61 eÅ−3, respectively, were located 0.87 and 0.39 Å from
the C18 and H23a atoms, respectively. In the refinement of 4, the C11-
cyclohexyl ring was disordered over two positions. Anisotropic refine-
ment but, with the displacement ellipsoids constrained to be nearly
isotropic, led to a site occupancy factor= 0.571(11) for the major
component. The maximum and minimum residual electron density
peaks of 1.15 and 1.32 eÅ−3, respectively, were located 0.98 and 0.75 Å
from the H26c and Ag1 atoms, respectively. Crystal data and refine-
ment details are collected in Table 1. The molecular structure diagrams
showing 70% probability displacement ellipsoids were generated by
ORTEP for Windows [29] and the packing diagrams with DIAMOND
[30]. Additional data analysis was made with PLATON [31]. Data for
1–4, in the form of Crystallographic Information Files (CIF's) have been
deposited with the Cambridge Structural Database with deposition nos:
1865251–1865254.
2.5. Anti-bacterial activity studies
2.5.1. Preparation of test organisms
A total of 12 clinically important pathogens were used in this study
and these were purchased from either the American Type Culture
Collection (ATCC) or the Malaysian Type Culture Collection (MTCC).
Five Gram-positive bacteria, i.e. Enterococcus faecalis (ATCC 33186), a
clinical isolate of methicillin-resistant Staphylococcus aureus (MRSA)
(MTCC 381123), Staphylococcus epidermidis (ATCC 700576),
Streptococcus pneumoniae (ATCC 49619) and Streptococcus pyogenes
(ATCC 49399), and seven Gram-negative bacteria, i.e. Escherichia coli
(ATCC 11775), Escherichia coli (MTCC 710859), Klebsiella pneumoniae
(ATCC 13883), Klebsiella quasipneumoniae (ATCC 700603),
Pseudomonas aeruginosa (ATCC 10145), Proteus mirabilis (ATCC 25933)
and Salmonella enterica (ATCC 14028). Fastidious bacteria, S. pneumo-
niae and S. pyogenes, were cultured in Mueller-Hinton Broth (MHB)
(Oxoid), while all remaining bacteria were cultured in Nutrient Broth
(NB) (Oxoid) and grown overnight at 37 °C prior to experiments.
2.5.2. Disc diffusion
The disc diffusion method was used to screen for anti-bacterial ac-
tivity of the synthesised compounds in accordance with the Clinical and
Laboratory Standards Institute (CLSI) guidelines. An inoculum suspen-
sion of each bacterial strain was prepared by adjusting the overnight
bacterial culture to 0.5 McFarland turbidity standard, corresponding to
approximately 108 colony forming units CFU/mL. The inoculum was
swabbed on the surface of Mueller-Hinton agar (MHA) (Oxoid) plates
using a sterile cotton swab. The test compounds were taken up in di-
methylsulphoxide (DMSO; Merck) to achieve a test concentration of
2mg/mL; 1 and 2 were suspensions. Sterile 6mm filter paper discs
were aseptically placed on MHA surfaces and 5 μL of the dissolved test
compound was added to the discs, making the total amount of trial
compound 10 μg/disc. Each plate contained two different types of
standard anti-biotic paper discs, chloramphenicol (30 μg/disc) and
tetracycline (30 μg/disc), which served as positive controls, one disc
served as the negative control (5 μL MHB), one disc served as solvent
control (5 μL DMSO) and two discs were used to evaluate the anti-
bacterial property of the trial compound. The plates were incubated for
24 h at 37 °C. The anti-bacterial activity was evaluated by measuring
the diameter of inhibition zones. Each experiment was performed in
triplicate.
2.5.3. Determination of minimum inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC)
A broth micro-dilution method was used to determine the MIC and
MBC values of the test compounds using CLSI protocols. Each test
compound (5 μL) was added into the wells of a 96-well microplate
containing 105 CFU/mL exponentially growing bacterial cells. The 96-
well microplates were incubated at 37 °C for 24 h. The final tested
concentrations ranged from 0.045 to 100mg/mL. All tests were per-
formed in triplicate. Four controls comprising medium with standard
anti-biotics, chloramphenicol and tetracycline (positive control),
medium with DMSO (solvent control), medium with inoculum bacterial
cells (negative control) and medium with broth only (negative growth
control) were included in each test. As an indicator of bacterial growth,
50 μL of 0.2mg/mL p-iodonitrotetrazolium violet (Sigma-Aldrich) was
added into each well; the presence of bacterial activity will convert the
dye from colourless to purple. The microplates were further incubated
for at least 30min under aerobic agitation. The MIC was determined as
the lowest concentration at which there is no trace of purple. After MIC
determination, an aliquot of 100 μL from each well which showed no
visible growth was spread onto MHA and further incubated at 37 °C for
24 h. The MBC was defined as the lowest concentration of the tested
compound that produced a 99.9% reduction in bacterial viable count on
MHA.
2.5.4. Time-kill assay
Time-kill assays were performed using the broth macro-dilution
method in accordance with the CLSI guidelines. Inoculum suspensions
with approximately 105 CFU/mL of exponentially growing bacterial
cells were used in this study. The test compound (100 μL) was added to
10mL of inoculum suspensions with final concentrations corresponding
to ½×MIC, 1×MIC and 2×MIC as determined earlier. A growth
control comprising the bacterial strain without the test compound was
included in each trial. The inoculum cultures were incubated at 37 °C
on an orbital shaker at 200 rpm. A total of 200 μL was removed from
each inoculum culture after time intervals of incubation (0, 1, 2, 3, 4, 8
and 24 h) and ten-fold serial dilutions were prepared in 0.85% normal
saline. The numbers of viable cells were determined by the plate count
technique which involved plating 25 μL of each dilution on a MHA
plate. All plates were incubated at 37 °C for 24 h. The experiments were
performed in triplicate. Data were analysed as killing curves by plotting
the log10[colony forming unit per millilitre (CFU/mL)] versus time (h),
and the change in bacterial number was determined. The viable bac-
terial cell count for the time-kill end point determination, e.g.
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bactericidal activity, is defined as a reduction of ≥3 log10(CFU/mL)
relative to the initial inoculum, whereas the bacteriostatic activity
corresponds to< 3 log10(CFU/mL) decrease relative to the initial in-
oculum.
2.5.5. Cell viability assay
The cytotoxicity effects of the test compounds were evaluated using
a normal cell line, i.e. human embryonic kidney cells (HEK 293). The
HEK 293 cells were seeded in a 96-well plate with a density of 1×105
cells to a final volume of 100 μL per well. The test compounds were
prepared by dissolution in DMSO to a concentration of 12mg/mL,
further diluted in Roswell Park Memorial Institute (RPMI)-1640
medium and then added to the well to obtain a final concentration of 0
(untreated control), 0.2, 0.4, 0.6, 0.8, 1 and 0.12mg/mL. The treated
HEK 293 cells were then incubated for 24 h. To investigate the cyto-
toxicity value of the test compounds, 20 μL of MTT (3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) solution (5mg/
mL in phosphate-buffered saline (PBS)) was added to each well and the
plate was further incubated for 4 h at 37 °C. Prior to analysis, the
medium was discarded and replaced with DMSO to dissolve the for-
mazan crystals (i.e. the reduced form of MTT, (E/Z)-5-[4,5-di-
methylthiazole-2-yl]-1,3-diphenylformazan) that had formed. The ab-
sorbance was measured at 570 nm through microplate reader (Tecan
Infinite-M200). The 50% inhibitory concentration (IC50) of each test
compound was determined by plotting the graph of percentage of
surviving cells against the concentration of the test compound. The
assay was performed in triplicate.
3. Results and discussion
3.1. Chemistry and X-ray crystallography
The bis{tricyclohexylphosphanesilver(I) dithiocarbamate} com-
pounds, 1–4, Fig. 1, were prepared in good yield employing the me-
tathesis reaction between AgNO3 and the respective dithiocarbamate
salt in the presence of Cy3P. The colourless compounds are air- and
light-stable for at least a month; spectroscopic data are collated in
Section 2.3. The IR spectra featured the anticipated bands due to
ν(CeN) and ν(CeS) of the dithiocarbamate ligands. The expected re-
sonances and integration were observed in the 1H NMR. Similarly, the
expected resonances were observed in the 13C{1H} spectra. Doublets
were observed in all 31P{1H} spectra due to JP-Ag coupling, and in all
spectra but that of 3, these were resolved owing to coupling with the
individual 107Ag/109Ag nuclei. The JP-Ag coupling constants for 1–4 are
in close agreement with those reported for related phosphanesilver(I)
complexes [32]. The stabilities of 1–4 were monitored by 31P{1H}
NMR. Compounds 1 and 2 were not particularly soluble in d6-DMSO
and hence, their stability over time could not be reliably determined in
this medium. By contrast, 3 and 4 were stable in d6-DMSO solution for
at least three days. Additional stability experiments were performed in
CDCl3 solution, again using 31P{1H} NMR. While 1 was stable for at
least three days, some decomposition and precipitation was evident for
2–4 after the egress of time with the most noteworthy feature being the
appearance of a resonance due to tricyclohexylphosphane oxide
(Cy3P]O) at approximately 50 ppm. Based on integration, approxi-
mately 5–10% decomposition had occurred after 24 h; spectra are given
in Supplementary materials Fig. S1.
Crystals suitable for X-ray crystallography were obtained for 1–4.
The molecular structure of 1, is located about a centre of inversion, is
shown in Fig. 2a. The structure features a μ2-bridging dithiocarbamate
ligand whereby the S1 atom bridges two silver(I) centres with disparate
AgeS1 bond lengths of 2.5781(3) and 2.8334(3) Å, and with the S2
atom [2.5976(3) Å] closes a four-membered AgS2C chelate ring. The
participation of the S1 atom in two AgeS bonds results in an elongation
in the C1eS1 bond compared with the C1eS2 bond, i.e. 1.7333(13) vs
1.7136(13) Å. The four-coordinate geometry for silver is completed by
the phosphane-P atom which forms the shortest of the four bonds to
silver [2.4148(3) Å]. The PS3 donor set is highly disordered with the
angles ranging from an acute 66.585(9)° for the S1eAgeS2 chelate
angle to a wide 121.668(11)° for S1eAgeP1. The Ag2C2S4 atoms have
the arrangement of a step ladder, with the chelate rings lying above and
below the central Ag2S2 rectangle. Finally, the transannular Ag⋯Ag
separation is 2.96470(19) Å.
The molecule in 2, which lacks the crystallographic symmetry of 1,
is shown in Fig. 2b; selected interatomic parameters are given in the
figure caption. In 2, a major structural reorganisation has occurred in
that the dithiocarbamate ligands lie to the same side of the central
Table 1
Crystal data and refinement details for 1–4.
Compound 1 2 3 4
Formula C46H86Ag2N2P2S4 C46H82Ag2N2P2S4 C46H86Ag2N2O4P2S4 C44H82Ag2N2O2P2S4
Formula weight 1073.08 1069.05 1137.08 1077.03
Crystal colour Colourless Colourless Colourless Colourless
Crystal size/mm3 0.12× 0.12× 0.15 0.06× 0.07× 0.11 0.05×0.08× 0.09 0.03× 0.06× 0.09
Crystal system Triclinic Triclinic Triclinic Triclinic
Space group P1 P1 P1 P1
a/Å 9.9960(2) 11.57530(10) 10.42860(10) 10.3452(2)
b/Å 11.1286(2) 12.37100(10) 11.31020(10) 14.5439(2)
c/Å 12.4674(3) 18.7114(2) 11.8927(2) 16.9693(2)
α/° 105.922(2) 97.6640(10) 107.0080(10) 75.4140(10)
β/° 98.259(2) 106.9900(10) 96.4390(10) 89.6250(10)
γ/° 99.0760(10) 98.7240(10) 101.4560(10) 86.6510(10)
V/Å3 1291.22(5) 2487.70(4) 1292.79(3) 2466.60(7)
Z 1 2 1 2
Dc/g cm−3 1.380 1.427 1.461 1.450
F(000) 564 1120 596 1128
μ(Cu Kα)/mm−1 8.409 8.729 8.493 8.838
Measured data 32,683 59,421 32,765 62,963
θ range/° 3.8–75.3 3.7–67.1 4.0–75.3 3.2–75.3
Unique data 5351 8901 5340 10,179
Observed data (I≥2.0σ(I)) 5332 8311 5174 9416
No. parameters 255 515 277 568
R, obs. data; all data 0.016; 0.041 0.024; 0.059 0.017; 0.041 0.032; 0.081
a; b in weighting scheme 0.019; 0.609 0.027; 2.256 0.017; 0.643 0.045; 2.033
Rw, obs. data; all data 0.016; 0.041 0.026; 0.061 0.018; 0.042 0.035; 0.084
Range of residual electron density peaks/eÅ−3 −0.38–0.31 −0.61–1.15 −0.39–0.41 −1.32–1.15
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Ag2S2 rectangle so that the arrangement of Ag2C2S4 atoms is a boat, cf.
the step-ladder observed in 1. The trends in the relative lengths of the
AgeS are also different so that the central Ag2S2 core resembles a
square, albeit being somewhat folded with the dihedral angle between
the two Ag2S planes being 13.94(4)°; the disparity in the CeS bonds
persists as for 1. The distortions from a regular tetrahedral geometry are
greater in 2. The most acute angle is still the chelate angle of 68.01(6)°
[70.008(16) for the Ag2 centre] while the widest angle is 141.69(9)°
formed by S1eAg1eP1, i.e. involving the most tightly bound atoms; for
the Ag2 centre, the equivalent angle, S3eAg2eP2, is 139.685(18)°. A
consequence of the reorganisation of the central core is an elongation in
the Ag1⋯Ag2 separation in 2, 3.617(2) Å cf. 2.96470(19) Å in 1.
The molecular structure of centrosymmetric 3 follows that estab-
lished for 1, Fig. 2c, including the variations in the AgeS and CeS bond
lengths, and Ag⋯Ag separation. Similarly, the range of angles sub-
tended at the Ag atom follow that observed in 1, i.e. the chelate angle
[55.109(11)°] is the most acute and the S1eAgeP1 angle is the widest
at 125.646(13)°. The final structure to be described is that of 4 for
which the crystallographic asymmetric unit comprises two independent
centrosymmetric molecules, i.e. two half molecules, Fig. 2d and Sup-
plementary materials Fig. S2. Each of the independent molecules adopts
the same structural motif as found for 1 and 3. The trends in the bond
lengths also follow those established above. A distinction between the
molecules is found in the tetrahedral angles. While the trend in tetra-
hedral angles for the Ag1-containing molecule follow those seen for 1
and 3, for the Ag2-molecule, the S3eAg2eP2 and S4eAg2eP2 are very
similar, both being approximately 122°.
The molecular packing of 1 features cyclohexyl-methylene-CeH⋯S
(dithiocarbamate) interactions whereby adjacent methylene-H atoms of
a cyclohexyl ring bridge sulphur atoms derived from two different di-
thiocarbamate ligands of an adjacent binuclear molecule. These inter-
actions lead to a supramolecular chain aligned along [1 0 0], Fig. 3a;
chains pack without directional interactions between them, Supple-
mentary materials Fig. S3; details of the geometric parameters char-
acterising the interatomic parameters are given in the relevant figure
captions of the Supplementary materials.
The only interaction between molecules identified within the stan-
dard distance criteria assumed in PLATON [31], is a CeH⋯π(chelate
ring) interaction. Such CeH⋯π(chelate ring) interactions are now well
known in the supramolecular chemistry of metal complexes, including
those of dithiocarbamates, owing to the high delocalisation of π-elec-
tron density in the MS2C chelate rings formed by dithiocarbamate li-
gands [33–35]. As illustrated in Fig. 3b, the CeH⋯π(chelate ring) in-
teractions connect binuclear molecules into a supramolecular dimer;
Fig. 2. Molecular structures of (a) centrosymmetric 1; symmetry operation (i) 1− x, 2− y, 1− z, (b) 2. Selected geometric parameters: Ag1eS1=2.571(2),
Ag1eS2= 2.779(3), Ag1eS4= 2.6742(19), Ag1eP1=2.327(2), Ag2eS3= 2.5452(5), Ag2eS4= 2.6796(5), Ag2eS2= 2.7128(5) and Ag2eP2=2.3691(5) Å,
(c) centrosymmetric 3; symmetry operation (ii) −x, −y, 1− z. Selected geometric parameters: AgeS1= 2.5574(4), AgeS1ii= 2.9920(5), AgeS2ii = 2.6054(4),
AgeP1=2.4239(4), Ag⋯Agii 2.9287(2) Å and (d) the first crystallographically independent and centrosymmetric molecule of 4; symmetry operation (iii) −x, 1− y,
1− z. Selected geometric parameters: Ag1eS1= 2.9856(7), Ag1eS1iii = 2.5446(6), Ag1eS2= 2.5818(7), Ag1eP1=2.4197(6), Ag1⋯Ag1iii 2.9014(4) Å;
S1eAg1eS2= 64.848(19), S1eAg1eP1iii = 125.37(2)°.
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these stack in columns parallel to the a-axis without directional inter-
actions between them, Supplementary materials Fig. S4.
The presence of hydroxyl groups in each of 3 and 4 leads to the
possibility of conventional hydrogen bonding in their crystals. In 3,
both intra- and inter-molecular hydroxyl-OeH⋯O(hydroxyl) hydrogen
bonds are formed, leading to centrosymmetric eight-membered
{⋯HO}4 synthons and supramolecular chains along [1 1 0], Fig. 3c. The
chains are connected into a supramolecular layer in the ab-plane by
cyclohexyl-methylene-CeH⋯O(hydroxyl), S(dithiocarbamate) interac-
tions as shown in Supplementary materials Fig. S5a; the layers stack
along the c-axis without specific interactions between them, Supple-
mentary materials Fig. S5b. In the crystal of 4, rather than hydroxyl-
OeH⋯O(hydroxyl) hydrogen bonds, hydroxyl-OeH⋯S(dithiocarba-
mate) hydrogen bonds are formed instead. As shown in Fig. 3d and
Supplementary materials S6a, these sustain centrosymmetric 14-mem-
bered {⋯HOC2NCS}2 synthons which alternate with the Ag2C2S4 rings
along the a-axis and, at the same time contribute to much larger 50-
membered {⋯SAgS⋯HOC2NCS⋯HOC2NCSAgSCNC2OH}2 synthons
incorporating six hydroxyl-OeH⋯S(dithiocarbamate) hydrogen bonds
and aligned along the c-axis. The resulting supramolecular layers stack
along the b-axis without directional interactions between them Sup-
plementary materials Fig. S6b.
An evaluation of the Cambridge Structural Database (CSD) [36]
indicates there are seven structures available in the literature of the
general formula [R3PAg(S2CNRR′)]2 for R, R′, R″= alkyl or aryl. There
are no literature precedents with Cy3P as the phosphane ligand nor one
with pyrrolidinedithiocarbamate. It is noted that each of the known
structures [37–41] adopts the step-ladder structural motif as described
above for 1, 3 and 4. Interestingly, there are four structures of the
analogous copper(I) derivatives. Consistent with the above, each of the
binuclear structures of [R3PCu(S2CNEt2)]2 for R=Me, Et and OMe
[42] is centrosymmetric implying a step-ladder motif. However, the
recently described structure of {Cy3PCu[S2CN(CH2)4]}2 [43], i.e. di-
rectly analogous to 2, adopts the same boat form as for 2. Clearly,
systematic structural studies are required to ascertain the reason(s), e.g.
steric and/or electronic, for these structural variations.
In terms of related structures with tetrahedrally-coordinated silver
within a PS3 donor set, there are over 100 examples included in the CSD
[36]. However, there is only a sole example having Cy3P as the phos-
phane ligand, namely Cy3PAg[(phenyl-tris(3-methyl-2-thioxoimidazol-
1-yl)borate-S,S′,S″)] [44]. In this structure, with two independent mo-
lecules in the asymmetric unit, the AgeP bond lengths are experi-
mentally equivalent at 2.3958(7) and 2.3980(7) Å, whereas the AueS
bond lengths span a range 2.5692(8) to 2.6530(9) Å. In the structures of
1, 3 and 4, where the central ring adopts the conformation of a step-
ladder, the AgeP bond lengths are systematically longer and the AgeS
bond lengths span a greater range that the literature structure, ob-
servations traced to the steric crowding in the molecules. For 2, the
AgeP bond length is marginally shorter than those in the literature
structure and the AgeS bond lengths span a similar range of values.
3.2. Anti-bacterial activity
For all biological trials, only freshly prepared solutions were used.
The Kirby-Bauer disc diffusion method was used in the initial screening
for the anti-bacterial properties of dithiocarbamate ligands, 1–4, AgNO3
and standards (Table 2). The solvent used in this study, i.e. DMSO, did
not produce an inhibition zone, suggesting DMSO does not exert anti-
bacterial effects on the tested bacterial strains. The results also showed
that the −S2CNR(CH2CH2OH) anions, for R=CH2CH2OH and Me, do
not have anti-bacterial activity against the tested bacterial strains while
the −S2CNEt2 anion showed low activity, having an effect on only one
Gram-positive bacterium (S. epidermidis), but not Gram-negative bac-
teria. By contrast, the −S2CN(CH2)4 anion was mildly active against all
Gram-positive bacteria and one Gram-negative bacteria (K. pneumoniae
ATCC 13883).
Enhanced anti-Gram positive bacterial activity was observed when
each of the dithiocarbamate anions were incorporated in the silver
Fig. 3. Molecular packing in: (a) 1, supramolecular chain parallel to the a-axis sustained by cyclohexyl-methylene-CeH⋯S(dithiocarbamate) interactions, shown as
orange dashed lines, (b) 2, supramolecular dimer sustained by cyclohexyl-methylene-CeH⋯π(Ag2,S3,S4,C24) interactions, shown as purple dashed lines, (c) 3,
supramolecular chain sustained by hydroxyl-OeH⋯O(hydroxyl) hydrogen bonding, shown as orange dashed lines and (d) 4, supramolecular layer sustained by
hydroxyl-OeH⋯S(dithiocarbamate) hydrogen bonding, shown as orange dashed lines; only the α-C carbon atoms of the cyclohexyl rings are shown. In each of
(a)–(d), non-participating hydrogen atoms have been omitted for clarity.
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compounds, 1–4; 1–4 exhibited no activity against Gram-negative
bacteria. Comparing the R= alkyl species, 1 and 2, 2 tends to be
marginally more potent than 1 exhibiting anti-bacterial effects against
all Gram positive bacteria, except for S. aureus (MRSA). The differences
in potency exhibited by 1–4 against the Gram-positive bacteria were
generally small with the exception against S. pyogenes. S. pyogenes, an α-
haemolytic bacterium implicated in Streptococcal pharyngitis, also
known as Strep Throat, appeared to be the most susceptible among the
tested clinically important Gram-positive bacteria [45]. Despite S.
pyogenes being an important medical pathogen, its biology, such as
integrity of cell wall, the presence of efflux pumps (that can pump out
anti-bacterial agents), etc. is not well documented [45] so the apparent
enhanced efficacy of 1–4 is of interest and worthy of further in-
vestigation. Compared with 1 and 2, the derivatives with CH2CH2OH
substituents were generally more potent with 3 being the most active
among the series against S. pneumoniae (9 mm) and 4 being most potent
against both S. pyogenes (12mm) and S. epidermidis (10mm). Crucially,
both 3 and 4 exhibit anti-bacterial activity against S. aureus (MRSA)
with inhibition zones of 9 and 7mm, respectively.
The disc diffusion results demonstrated that compounds 1–4 were
specifically effective against Gram-positive bacteria but not Gram-ne-
gative bacteria. The selective activity against only Gram-positive bac-
teria leads to the speculation that the permeability barrier of the outer
membrane present in Gram-negative bacteria limits the entry of com-
pounds 1–4. The Gram-negative cell outer membrane contains lipopo-
lysaccharides in its outer leaflet and phospholipid in its inner leaflet
that are known to effectively exclude several drugs compared to Gram-
positive bacteria [46]. Similar anti-bacterial selectivity effects were
observed for the previously studied silver, copper and gold dithio-
carbamates [22–24].
Trials were also conducted on AgNO3. It is interesting to note that
AgNO3 was non-specific in terms of inhibiting Gram-positive and Gram-
negative bacteria indicating the presence of the dithiocarbamate li-
gands in 1–4 introduces specificity in activity. The clinically-employed
anti-biotics chloramphenicol and tetracycline (each 30 μg/disc) were
included in this study as controls. These drugs produced respectively,
large inhibition zones of 30–39 and 28–38mm against Gram-positive
bacteria, and 10–28 and 11–31mm against Gram-negative, Table 2.
These differences in activity against Gram-positive bacteria are largely
due to the lower concentrations employed for 1–4 (10 μg).
3.3. Determination of minimum inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC)
The disc diffusion assay showed that two of the dithiocarbamate
anions and 1–4 exhibited anti-bacterial activity. This activity was fur-
ther quantitatively evaluated against Gram positive bacteria by de-
termining their MIC and MBC values with the results tabulated in
Table 3; the anti-biotics tetracycline and chloramphenicol were used as
positive controls.
In this study, 1–4 and dithiocarbamate ligands were not effective
against the tested Gram negative bacteria, except for the −S2CN(CH2)4
anion against K. pneumoniae; this gave an MIC value of 100 μg/mL and
was not studied further. The other active anion, −S2CNEt2, exhibited
anti-bacterial effects against only one Gram-positive bacterium, S. epi-
dermidis, with an MIC value of 100 μg/mL and again this was not stu-
died further. For −S2CNR(CH2)4, MIC values ranging from 12.5 to
50.0 μg/mL were observed for all Gram-positive bacteria. The anti-
bacterial effects of 1–4 were maintained or enhanced when compared
to their respective anions, except for 2 on S. aureus (MRSA). The en-
hanced inhibitory effects of 1–4 compared to the (charged) dithio-
carbamates might be due to an increase in the lipophilicity of (neutral)
1–4 [47,48]. The MIC values of 1–4 were in the range of 0.10–100 μg/
mL, whereas tetracycline was active in the range of 0.20–0.39 μg/mL
and chloramphenicol in the range of 1.56 to 6.25 μg/mL.
As a general observation, the MIC values of 3 and 4 against all tested
Gram-positive bacteria were lower than for 1 and 2, and significantly
lower than those produced by AgNO3. Compound 3 was effective in
inhibiting the growth of all tested Gram-positive bacteria with MIC
values in the range of 0.39 (S. epidermidis and S. pneumoniae) to
3.13 μg/mL (S. aureus (MRSA)). Compound 4 was the most effective
compound across the series, being most potent against S. epidermidis
with a MIC value of 0.10 μg/mL. It was also the most active against S.
pneumoniae (MIC=0.20 μg/mL), E. faecalis (0.78 μg/mL), S. pyogenes
(0.78 μg/mL) and S. aureus (MRSA) (1.56 μg/mL).
It was initially expected that 3, Cy3PAg[S2CN(CH2CH2OH)2], with
two hydroxyethyl groups, would be the most effective anti-bacterial
agent as the second hydroxyethyl functional group might allow for the
formation of additional hydrogen bonding interactions with biological
substrates, leading to the impairment of normal cellular processes in
bacterial cells [49]. However, the results showed 4, Cy3PAg[S2CN
(Me)CH2CH2OH], with a less polar group (methyl), was most active. It
is possible that the increased lipophilic character of 4 enables more
efficient diffusion across the membrane into the cytoplasm of bacterial
cells, before exhibiting its anti-bacterial effects [50].
Previous studies on a related gold(I) species, i.e. Cy3PAu[S2CN
(CH2CH2OH)2], gave MIC values in the range of 1.56–50.00 μg/mL
against all tested Gram-positive bacteria [24]. In the present study, the
MIC values obtained for compound 3, {Cy3PAg[S2CN(CH2CH2OH)2}2
were relatively lower than the MIC values for the aforementioned gold
Table 2
Anti-bacterial activity measured by zone of inhibition (mm) of the dithiocarbamate anions, 1–4 and AgNO3 (10 μg/disc) and standard anti-biotics (30 μg/disc).a,b,c
Microorganism −S2CNEt2 1 −S2CN(CH2)4 2 3 4 AgNO3 Tetracycline Chloramphenicol
Gram-positive bacteria
E. faecalis ATCC 33186 - 7 7 8 7 7 7 39 31
S. aureus (MRSA) MTCC 381123 - - 7 - 9 7 7 30 28
S. epidermidis ATCC 700576 7 9 7 8 9 10 8 38 38
S. pneumoniae ATCC 49619 - 8 7 8 9 8 8 34 30
S. pyogenes ATCC 49399 - 8 7 9 10 12 9 30 33
Gram-negative bacteria
E. coli ATCC 11775 - - - - - - 8 22 26
E. coli MTCC 710859 - - - - - - 8 25 31
K. pneumoniae ATCC 13883 - - 7 - - - 8 25 31
K. quasipneumoniae ATCC 700603 - - - - - - 8 17 15
P. aeruginosa ATCC 10145 - - - - - - 7 13 11
P. mirabilis ATCC 25933 - - - - - - 7 10 25
S. enterica ATCC 14028 - - - - - - 7 28 31
a The diameter of inhibition zones in millimetres were measured around the discs after 24 h incubation; -, no zone of inhibition.
b The dithiocarbamate anions −S2CN(CH2CH2OH)2 and −S2CN(Me)CH2CH2OH did not exhibit inhibition.
c The presented zones of inhibition are the minimum zones obtained from three independent experiments conducted in triplicate.
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derivative. This, coupled with observation that replacing one hydro-
xyethyl with a methyl group to yield 4 further enhanced the anti-bac-
terial activity, indicate that the new silver dithiocarbamates described
herein are potential potent anti-bacterial agents.
Given that inhibition of bacterial growth does not necessarily in-
dicate the ability of a test compound to kill a particular bacterium, the
minimum bactericidal concentration (MBC) was determined to identify
whether the test compound was able to kill a bacterium (bactericidal)
or only inhibited growth (bacteriostatic). Both bactericidal and bac-
teriostatic anti-biotics are used to treat a variety of bacterial infections.
Bactericidal anti-biotics can be taken for a short period of time and are
often used to reduce the risk/cure the infection better than bacterio-
static anti-biotics. It is noted that bacteriostatic anti-biotics are often
sufficient to treat an infection by slowing the growth of the bacteria
while the individual's immune system fights/eliminates the infection.
However, the infection may persist if a patient is immunocompromised
[51,52]. The knowledge on the use of either bactericidal or bacterio-
static agents is crucial for the effective treatment of an infected patient.
With this in mind, the bactericidal or bacteriostatic properties of 1–4
were investigated.
The generally accepted definition of MBC by Levison [53] is used
herein: an anti-bacterial agent is considered bactericidal if the value of
MBC is not more than four-fold greater than the MIC, i.e. MBC/
MIC≤4. The anti-bacterial properties of 1–4 against susceptible strains
were analysed by the MBC assay and the results are summarised as
MBC/MIC ratios in Table 3. For the chosen Gram-positive bacteria,
chloramphenicol (see below) and tetracycline were bacteriostatic.
While AgNO3 was bactericidal against all tested bacteria, this is not
potent. For compounds 1 and 2, bactericidal activity was proven
against S. pyogenes and S. epidermidis. Compounds 3 and 4 were shown
to be bactericidal (MBC/MIC≤2) toward all the susceptible Gram-
positive strains, except against S. pneumoniae, with the MBC being 16-
fold greater than the MIC, indicating these are bacteriostatic. These
results indicate that the bactericidal and bacteriostatic activities of 1–4
are dependent on the bacterial strain. This behaviour is similar to
standard anti-biotic, chloramphenicol which is considered bacterio-
static against most Gram-positive and many Gram-negative aerobic
bacteria by binding to the 50S subunit of the bacterial 70S ribosome
which causes inhibition of protein synthesis [54]. However, bacter-
icidal activity on some bacteria, such as H. influenzae, S. pneumoniae and
N. meningitidis, has also been reported which enables the use of chlor-
amphenicol in the treatment of meningitis caused by the mentioned
pathogens [55]. Similar variable bactericidal/bacteriostatic activities
were also reported for related phosphanegold(I) dithiocarbamates [23].
Disc diffusion and MIC are two standard assays used in the de-
termination of anti-bacterial properties. The presence of a zone of in-
hibition indicates anti-bacterial potential and it is expected MIC tests
would support the results. However, in this present study, a positive
correlation was not observed for these two independent experiments.
For instance, based on the MIC results, at 0.10 μg/mL, 4 was shown to
be the most effective against S. epidermidis, but 4 only produced a
10mm of zone of inhibition against S. epidermidis while the comparable
result against S. pyogenes, with a MIC value of 0.78 μg/mL, has a zone of
inhibition of 12mm. Comparing the two assays, disc diffusion makes
use of solid media while MIC uses liquid media. It is thought that the
diffusion and mobility of the silver compounds in the solid medium is
restricted, leading to poor diffusion through agar medium and thus
moderate zones of inhibition are observed. Similar observations were
made for related tin dithiocarbamates [50].
3.4. Time kill assay
Time kill assays provide useful information to describe the phar-
macodynamics of trial anti-bacterial compounds [56]. In contrast to
MIC determinations, which involve the study of the anti-bacterial effect
at one concentration after a specific time, the time kill assayTa
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investigates the effect of three different concentrations of 1–4, ½×, 1×
and 2×MIC, over a 24 h incubation period. According to CLSI proto-
cols, a 3 log10 CFU/mL or greater reduction in the viability of the bac-
terial colony relative to the initial inoculum is the point that differ-
entiates between bactericidal and bacteriostatic activity [57]. The
pharmacodynamics of 1–4 (Table 4 and Figs. 4–7) as well as chlor-
amphenicol and tetracycline (Supplementary materials Table S1 and
Figs. S7 and S8) against susceptible bacterial strains were determined
using time kill assays; the standards were uniformly bacteriostatic
against the tested bacteria.
As expected from the determined MBC/MIC ratios in Table 3, the
time kill assays for 1 and 2 toward E. faecalis and S. pneumoniae at
1×MIC indicated they were bacteriostatic whereas toward S. epi-
dermidis and S. pyogenes exhibited bactericidal behaviour. At 1×MIC,
1 and 2 were bactericidal toward S. epidermidis after 1 h, and after 4 h
toward S. pyogenes. At 2×MIC, 1 was bactericidal toward S. epidermidis
and S. pneumoniae after 1 h, and after 2 h for S. pyogenes. The latter
result indicated 1 demonstrates rapid concentration-dependent
bactericidal activity against S. pyogenes. Under the same conditions, 2
exhibited similar bactericidal effects as 1 toward S. epidermidis after 1 h
at 2×MIC. Compound 2 was also bactericidal toward S. pyogenes after
4 h at 2×MIC. Therefore, the killing rate of 2 was slower than 1
against S. pyogenes.
The common feature of the time kill assays for 3 and 4 were that all
were bactericidal against all bacteria with the notable exception of S.
pneumoniae. Compound 3 demonstrated rapid concentration-dependent
bactericidal activity against S. pyogenes. At 1×MIC and 2×MIC,
bactericidal activity was achieved at 4 and 1 h, respectively, against S.
pyogenes. By contrast, against E. faecalis, time to achieve 3 log10 kill was
similar at 1×MIC and 2×MIC. As a general observation, at 2×MIC
concentrations bactericidal effects were noted only after 4 h for E.
faecalis and S. aureus (MRSA), 2 h for S. epidermidis and 1 h for S. pyo-
genes. Two of these, E. faecalis and S. pyogenes, were also susceptible at
1×MIC after 4 h.
For 4, the required time to achieve 3 log10 kill was similar at
1×MIC and 2×MIC against E. faecalis, S. aureus (MRSA), S.
Table 4
Summary of in-vitro time-kill assay of 1–4 against susceptible pathogen strains.
Microorganism Compound Log10 CFU/mLa
½×MIC 1×MIC 2×MIC
1 h 2 h 4 h 8 h 24 h 1 h 2 h 4 h 8 h 24 h 1 h 2 h 4 h 8 h 24 h
E. faecalis ATCC 33186 1 +0.1 +0.1 +1.0 +3.3 +3.4 0.0 −0.1 +1.0 +3.2 +3.3 −0.2 −0.2 +0.8 +3.1 +3.3
2 −0.1 +0.1 +0.8 +3.2 +3.5 −0.1 −0.1 +0.3 +2.9 +3.4 −0.3 −0.1 +0.1 +2.0 +3.4
3 −0.8 −0.5 −1.5 −1.5 +4.7 −0.8 −0.7 −4.4 −4.4 +4.6 −1.4 −0.9 −4.4 −4.4 +3.3
4 −0.1 −0.4 0.0 +0.1 +3.5 −0.1 −4.7 −0.2 0.0 +3.5 −0.3 −4.7 −4.7 −4.7 +3.5
S. aureus (MRSA) MTCC 381123 3 −0.2 −0.1 −0.8 −0.6 +4.8 −0.3 −0.4 −2.2 −1.6 +2.7 −0.4 −0.6 −5.2 −2.2 +0.8
4 −0.3 −0.4 +0.6 +2.7 +5.1 −0.3 −5.2 +0.1 +0.1 +3.0 −0.5 −5.2 −5.2 −0.9 +2.6
S. epidermidis ATCC 700576 1 +0.3 +0.3 +1.0 +1.2 +4.0 −3.3 +0.2 +0.7 +1.1 +3.9 −3.5 −3.5 +0.5 +1.0 +3.7
2 +0.3 +0.3 +0.7 +1.2 +4.4 −3.5 0 +0.3 +0.9 +4.0 −3.5 −3.5 −0.2 +0.6 +3.5
3 +0.1 +0.1 −0.2 0.0 +4.0 −0.3 −0.3 0.0 +0.2 +3.7 −0.5 −3.5 −0.5 −0.2 +3.4
4 +0.3 0.0 +0.3 +1.1 +4.4 0.0 −3.3 0.0 +0.8 +4.0 −0.5 −3.5 −3.5 +0.5 +3.7
S. pneumoniae ATCC 49619 1 −0.2 −0.2 +0.5 +2.6 +4.0 −0.3 −0.6 +0.4 +2.5 +3.8 −4.1 −4.1 +0.3 +2.2 +3.4
2 +0.1 +0.2 +0.4 +1.6 +4.1 +0.1 +0.1 +0.2 +1.4 +3.9 0.0 0.0 0.1 +1.1 +3.3
3 −0.1 +0.1 +0.1 +1.7 +4.7 −0.1 0.0 0.0 +1.5 +4.8 −0.2 0.0 −0.1 +1.1 +4.6
4 0.0 −0.1 +0.5 +2.4 +4.8 0.0 −0.3 +0.3 +2.2 +4.7 −0.6 −1.1 −0.2 +2.0 +4.6
S. pyogenes ATCC 49399 1 +0.1 0.0 +0.3 +1.2 +3.8 0.0 −1.0 −4.5 +0.5 +3.7 −0.1 −4.5 −4.5 −0.5 +3.6
2 +0.1 +0.1 −0.7 +0.3 +3.9 +0.1 0.0 −4.5 −4.5 +3.8 −0.2 −0.1 −4.5 −4.5 +3.8
3 −0.5 −0.2 −1.0 −0.5 +4.1 −0.8 −0.3 −3.8 −3.8 +4.2 −4.2 −4.2 −4.2 −4.2 +3.6
4 −0.3 −1.0 −0.6 +0.1 +3.2 −4.4 −4.4 −4.4 −0.5 +2.9 −4.4 −4.4 −4.4 −1.4 +1.6
a Relative to log10 CFU/mL of initial inoculum (a negative value indicates a reduction of bacterial cell number, and a positive value indicates an increase of
bacterial cell number). Values shown are the mean of triplicate determinations from each experiment.
Fig. 4. Time kill curves for 1: (a) E. faecalis, (b) S.
epidermidis, (c) S. pneumoniae and (d) S. pyogenes.
The bactericidal level is indicated by the dashed lines
— negative control ×, ½×MIC ♦, 1×MIC ■ and
2×MIC▲.
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epidermidis (all 2 h) and S. pyogenes (1 h) at both 1×MIC and 2×MIC
concentrations.
The emergence of the multi-drug resistant bacterium, S. aureus
(MRSA), is recognised as a serious health threat to the general public by
the Centers for Disease Control and Prevention (CDC) as this rapidly
develops resistance to new anti-biotics. In 2011, Vidaillac et al. [58]
examined the in vitro activity of three anti-biotics commonly used in
the treatment of S. aureus (MRSA) infections, namely oritavancin,
vancomycin and teicoplanin. It was reported that oritavancin exhibited
rapid bactericidal activity against S. aureus (MRSA) at 4×MIC after 9 h
exposure while both vancomycin and teicoplanin achieved a maximum
2.7 log10 CFU/mL decrease against S. aureus (MRSA) at 8×MIC. In the
present study, the kill kinetic profile of 4 showed a far more rapid
bactericidal activity i.e. within 2 h at 2×MIC, compared to or-
itavancin. Also, 4 reached a maximum 5.2 log10 CFU/mL decrease
against S. aureus (MRSA) at 2×MIC compared to vancomycin and
teicoplanin. The killing rate of 4 was faster than 3 against S. aureus
(MRSA) in which bactericidal activities were seen after 2 h to achieve a
maximum 5.2 log10 CFU/mL decrease at 2×MIC. These results un-
derscore the promising utility of 3 and 4 as anti-bacterial agents.
Fig. 5. Time kill curves for 2: (a) E. faecalis, (b) S.
epidermidis, (c) S. pneumoniae and (d) S. pyogenes.
The bactericidal level is indicated by the dashed lines
—, negative control ×, ½×MIC ♦, 1×MIC ■ and
2×MIC▲.
Fig. 6. Time kill curves for 3: (a) E. faecalis, (b) S.
aureus (MRSA), (c) S. epidermidis, (d) S. pneumoniae
and (e) S. pyogenes. The bactericidal level is indicated
by the dashed lines —, negative control ×, ½×MIC
♦, 1×MIC ■ and 2×MIC▲.
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Notably, all strains were found to regrow to the same or almost the
same level as the control after 24 h at concentrations of 2×, 1× and
½×MIC. This phenomenon is common in studies of bacterial killing
rate of anti-microbial agents in time kill assays [59]. This may be due to
two different sub-populations with different susceptibility in which the
selective growing of resistant sub-population take over the preferential
killing of susceptible sub-population at specified time of interaction
[56].
In summary, compounds 3 and 4 are demonstrated to be more ef-
fective anti-bacterial agents compared to 1, 2 and AgNO3. Silver nitrate,
used in the synthesis of 1–4, is a known an anti-septic agent used in the
prevention of eye infections in the new-born children and is known to
be active against both Gram positive and Gram negative bacteria [8].
Considering the chemical structures, charge-neutral 3 and 4 are sig-
nificantly bulkier than the salt due to the presence of the tricyclohex-
ylphosphane and dithiocarbamate ligands. These characteristics ease
the diffusion of the compounds across the bacterial membrane before
they exhibit their anti-bacterial activity. The additional hydroxyl group
(s) in 3 and 4 impart significant effects in the anti-bacterial activity as
compared to 1 and 2, indicating that the ratio of hydrophobicity/hy-
drophilicity can be fine-tuned for the enhancement of in vitro anti-
bacterial activity. To determine the lipophilicity and hydrophobic
properties of the synthesised compounds, oil/water partition co-effi-
cient (in term of logP) in systems such as octanol/water and chloro-
form/water can be further investigated [60]. The anti-bacterial activity
of metal dithiocarbamates is suggested to arise by the inactivation of
physiologically important enzymes [14,61]. Thus, possible mechanisms
of action of 1–4 can be verified by investigating their inhibition of
enzymes such as SH-protease papain, NADP+-dependent alcohol de-
hydrogenase and the NAD+-dependent alcohol dehydrogenase [62].
3.5. Cytotoxicity
The possible cytotoxic effects of 1–4 were investigated through a
MTT assay conducted on a normal cell line, the HEK 293 human em-
bryonic kidney epithelial cell line, as an in vitro representative of a
normal cell model, at various concentrations, starting from 0, 8, 15, 30,
60 and 90 μM. The toxicity effects of 1–4 toward HEK 293 are presented
in Supplementary materials Fig. S8. The results indicated the percen-
tage of cell viability after 24 h treatment with 1–4 was observed
at> 80% against the six concentrations. The IC50 values were> 90 μM
indicating 1–4 are non-cytotoxic.
4. Conclusions
Four new binuclear phosphanesilver(I) dithiocarbamates, 1–4, have
been characterised and investigated for their anti-bacterial potential.
Based on MIC assays, 1–4 possess potent and selective anti-bacterial
activity against Gram-positive pathogens; 1–4 are non-toxic to human
embryonic kidney cells, HEK 293. Crucially, 3 and 4 are also potent
against S. aureus (MRSA), which is resistant to several classes of anti-
biotics. While interesting selectivity is noted, 4, with low MIC values
and more rapid bactericidal activity against S. aureus (MRSA), could
provide clinical advantages in bacteriostatic therapy for im-
munocompromised patients by rapid elimination of S. aureus (MRSA)
pathogens and thereby reduce the possibility of the spread of infection.
Based on the time-kill studies, the concentrations required and bacterial
killing rates of 1–4 were different from each other suggesting distinct
mechanisms of action. In summary, the new compounds show great
promise as effective anti-bacterial agents against Gram-positive bac-
teria. In particular, further investigations are warranted to determine
the therapeutic potential of compound 4 against S. aureus (MRSA).
Fig. 7. Time kill curves for 4: (a) E. faecalis, (b) S.
aureus (MRSA), (c) S. epidermidis, (d) S. pneumoniae
and (e) S. pyogenes. The bactericidal level is indicated
by the dashed lines —, negative control ×, ½×MIC
♦, 1×MIC ■ and 2×MIC▲.
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